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Open access undEndothelin-receptor antagonist/N-acetylcysteine combination
in type 1 hepatorenal syndromeTo the Editor:
Type 1 hepatorenal syndrome (HRS) is characterized
by a marked splanchnic arterial and systemic vasodilata-
tion ultimately resulting in an acute functional renal fail-
ure. Two recent, large, randomized controlled trials
conﬁrmed that terlipressin improved renal function,
only in 35% of these patients [1,2]. We report an
improvement of renal function using bosentan, a nonse-
lective endothelin-receptor antagonist, and N-acetylcys-
teine (NAC) association in a terlipressin/albumin
unresponsive type 1 HRS case.
A 49-year-old man with post-hepatitis B cirrhosis
(Child-Pugh score B8, large ascites) presented with a
3-day history of decompensation with jaundice (serum
bilirubin, 61 lmol/L), coagulopathy (international nor-
malized ratio, 2.70), grade II encephalopathy, and oli-
go-anuria (urine output less than 100 mL/24 h, serum
creatinine, 3.85 mg/dL) after resolution of spontaneous
bacterial peritonitis under adequate anti-biotherapy.
Medical past history was remarkable for chronic kidney
disease related to biopsy proven post-hepatitis B mem-
branoproliferative glomerulonephritis (baseline serum
creatinine, 1.70 mg/dL, proteinuria 3 g/day and hematu-
ria 200 red blood cells/high power ﬁeld). On admission,
there was no evidence of shock (mean arterial pressure,
80 mm Hg), gastrointestinal bleeding, or treatment with
nephrotoxic drugs. Proteinuria and hematuria were sta-
ble compared to previous renal status, and the kidneyssentan + N-acetylcysteine in type 1 HRS: renal and liver outcome
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er CC BY-NC-ND license.appeared normal on ultrasonography. Urinary so-
dium/potassium ratio was less than one. Although the
patient presented with medical history of glomerulone-
phritis, this current acute renal failure episode had all
the features of type I HRS [3], and the decision was
made to start a treatment with terlipressin and albumin.
Despite 72 h intravenous terlipressin 8 mg/24 h associ-
ated with adequate intravenous ﬂuid and albumin infu-
sion (1 g/kg at day 1 followed by 40 g/day), the patient
worsened his serum creatinine: 4.90 mg/dL urine output
dropped to <10 mL/24 h, and he developed pulmonary
oedema necessitating hemodialysis. Treatment including
oral endothelin antagonist (bosentan, 62.5 mg twice dai-
ly) and N-acetylcysteine (150 mg/kg over 2 h, followed
by a dose of 100 mg/kg daily for 5 consecutive days)
was instituted leading to early clinical improvement: ur-
ine output increased to 2000 mL daily, serum creatinine
decreased to baseline values (1.97 mg/dL) and dialysis
could be withheld. Table 1 illustrates the end-stage liver
disease score and renal parameters before and 2 weeks
after the above mentioned treatment.
The intrarenal production of endothelin has been
implicated in the development of renal vasoconstric-
tion, a key step that leads to the development of
HRS. However, the beneﬁt of the use of endothelin
antagonist in the management of HRS remains un-
clear. Bosentan prevented the development of renal
failure in a rat model of acute liver failure and in-s.
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duced a dose-related improvement of the glomerular
ﬁltration rate in humans [4,5]. In contrast, Wong
et al. showed that tezosentan, another nonselective
endothelin-receptor antagonist, has not been beneﬁcial
in the management of type 2 HRS in cirrhosis and re-
ported lack of eﬀects on renal function [6]. On the
other hand, intravenous NAC has also been reported
to be of some beneﬁt in HRS [7].
Considering that both drugs seem to be safe and have
some beneﬁcial role in HRS, the combination needs to
be further studied in patients with HRS.
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